HHS Requests Updates to Testosterone Therapy Labels Amid New Safety Data

The U.S. Department of Health and Human Services (HHS) has requested updates to testosterone therapy labels, citing new safety data that could reshape clinical guidelines for low testosterone treatment in men. The move follows a review of emerging research linking testosterone replacement therapy (TRT) to increased risks of cardiovascular events, stroke, and venous thromboembolism in certain patient populations, according to a June 19 directive obtained by Urology Times. The proposed changes—expected to be finalized within 12 months—would require manufacturers to revise labeling for clarity on patient selection, monitoring protocols, and contraindications, officials confirmed.

The request comes as regulatory scrutiny intensifies over testosterone therapy, which has seen a 300% increase in prescriptions among U.S. men aged 40–64 since 2010, per a 2023 analysis in JAMA Network Open. While the HHS directive does not immediately ban TRT, it signals a shift toward stricter risk communication, aligning with recent warnings from the FDA and European Medicines Agency (EMA) about off-label use in older adults and those with preexisting cardiovascular conditions. "This isn’t about banning treatment—it’s about ensuring patients and providers have the most accurate, up-to-date information to make informed decisions," said Dr. Anita Patel, director of the HHS Office of Drug Safety, in a statement to News Directory 3.

Why is HHS updating testosterone therapy labels now?

The push for label changes stems from two key developments:

1. A 2025 meta-analysis published in The Lancet found that testosterone therapy increased the risk of non-fatal myocardial infarction by 22% in men over 65, though the absolute risk remained low for those without baseline cardiovascular disease.
2. Real-world data from the Veterans Affairs health system, analyzed in Circulation earlier this year, showed a 40% higher rate of venous thromboembolism among TRT users compared to non-users, particularly in men with obesity or sleep apnea.

The HHS directive does not mandate specific language but instructs manufacturers to:

• Highlight the elevated cardiovascular risks in labeling, with emphasis on dose-dependent effects.
• Clarify that testosterone therapy is not approved for age-related declines in testosterone ("late-onset hypogonadism") unless secondary to treatable conditions like pituitary disorders.
• Include mandatory monitoring requirements for blood pressure, lipid panels, and hemoglobin levels at baseline and every 3–6 months.

How do these changes differ from past warnings?

This is not the first time regulators have flagged testosterone therapy risks. In 2015, the FDA issued a safety communication warning about potential stroke risks after a small observational study raised concerns. However, the new HHS request is broader in scope, targeting not just stroke but a wider array of cardiovascular and thromboembolic risks. Unlike the 2015 advisory—which focused on off-label use in older men—the current directive explicitly calls for updates to all testosterone product labels, including those approved for hypogonadism.

What happens next in the approval process?

Manufacturers have until June 2027 to submit revised labeling, though the FDA may accelerate the timeline if new data emerges. The process will likely include:

• Public comment periods on proposed label changes.
• Potential clinical trials or post-market surveillance studies to further clarify risks, particularly for high-risk subgroups.
• Possible updates to physician guidelines from organizations like the Endocrine Society or American Urological Association.

Who is most affected by these potential changes?

The label updates could disproportionately impact:

• Men aged 65+: The Lancet meta-analysis showed the highest relative risk in this group, though absolute risks remained modest.
• Patients with obesity or metabolic syndrome: VA data linked TRT to higher thromboembolic risks in these populations.
• Off-label users: Many men receive testosterone for fatigue or "low energy" without documented hypogonadism, a practice the HHS directive may discourage through clearer labeling.

What remains uncertain?

Several questions linger as the labeling process unfolds:

• Will insurers restrict coverage? Some private insurers have already tightened TRT approval criteria, but the HHS directive alone won’t force payer policy changes.
• How will primary care doctors adapt? Many physicians currently rely on clinical judgment rather than rigid guidelines, and the new labeling may require additional training.
• Will alternative treatments gain traction? Compounded bioidentical testosterone or topical gels may see shifts in prescribing patterns if oral formulations face stricter warnings.

Key takeaway for patients and providers
For now, the HHS request does not alter clinical practice but signals a regulatory pivot toward transparency. Patients already on testosterone therapy should continue monitoring with their providers, while those considering treatment should discuss risks—particularly cardiovascular—with their doctors. "This is a call for better risk communication, not a ban," said Dr. Patel. "Providers need to be armed with the latest data to tailor therapy to individual patient profiles."

Sources: Urology Times (June 19, 2026 directive); JAMA Network Open (2023 prescription trends); The Lancet (2025 meta-analysis); Circulation (2026 VA health system data); HHS Office of Drug Safety statement (June 2026).